Non-financial reporting
We create value for all our stakeholders and track our performance against key financial and non-financial indicators. These indicators are grouped under our main areas of engagement:
Key performance indicators (KPIs)
Innovating for patients
Ban katantaOur primary contribution to healthcare is to invent and develop medicines and diagnostics that significantly improve people’s lives. This entails a commitment to working with many different partners to continuously and sustainably reduce the barriers that prevent or impede access to our products.
-
See KPIs
KPI 2019 2018 2017 Number of patients treated with Roche medicines (1)
- Number of patients treated with off- patent medicines
- Number of patients treated with patented medicines
63,183,000
61,480,000
1,703,000
127,000,000
Ban katanta124,000,000
3,000,000
Ban katanta137,500,000
134,500,000
3,000,000
Number of tests conducted with Diagnostics products (in billions)
21.4
>20 19
Number of Roche medicines on the WHO list of essential medicines
32 30 30 Ban katantaNumber of patients included in clinical trials (2)
282,501 279,495 295,746
- % of patients participating from low and low-middle income countries (3) 1.02% 1.26% 1.10%
Number of new molecular entities (NMEs) in clinical development 72 67 72 Number of major regulatory filings completed (Pharmaceuticals) 11 16 10 Number of FDA Breakthrough Therapy designations 4 7 4 Number of new medicines launched (4) 2 1 3 Number of Diagnostics key product launches 9 11 14
Providing a great workplace
Ban katantaWe aim to provide a work environment where our employees are encouraged to build their careers and pursue their passions. By providing everyone with the opportunity for career development, we ensure the growth of our single largest investment – our employees – and, in turn, the success of our organisation.
-
See KPIs
KPI 2019 2018 2017 Number of employees (full-time equivalents - FTE) 97,735 ✔ PwC CH 94,442 93,734 - Roche Pharmaceuticals 48,012 ✔ PwC CH 47,079 49,825 - Chugai Pharmaceuticals 7,448 ✔ PwC CH 7,495 7,432 - Diagnostics Division 37,114 ✔ PwC CH 36,557 35,096 - Corporate 5,161 ✔ PwC CH 3,311 1,381 Percentage of temporary employees 2.8 % ✔ PwC CH 2.8% 2.4% Percentage of part time employees 7.8% ✔ PwC CH 6.3% 6.2% Percentage of total employees covered by collective bargaining agreements 17.0% ✔ PwC CH 18.0% 18.2% Number of postgraduates and interns 2,161 ✔ PwC CH 1,843 1,636 Percentage of women in total workforce 49.3% ✔ PwC CH 49.1% 49.0% Percentage of women in management 43.5% ✔ PwC CH 42.8% 42.1% Percentage of women on the Corporate Executive Committee 20.0% ✔ PwC CH 10.0% 18.2% Percentage of women on the Board 25.0% ✔ PwC CH 25.0% 25.0% Percentage of women in key leadership positions (5) 32.0% ✔ PwC CH 30.3% 27.7% Percentage of key leaders with diverse work experience
24.2% ✔ PwC CH 22.4% 23.5% Ban katantaPercentage of all key leadership positions vacancies filled internally
80.0% ✔ PwC CH 87.0% 92.0% Number of employees in international assignments in the given year 977 ✔ PwC CH 1,038 1,146 Percentage of cross-regional international assignments 37.3% ✔ PwC CH 37.1% 41.2% Total number of new employee hires 14,157 ✔ PwC CH 10,744 10,210 Internal recruitment rate 64.6% ✔ PwC CH 62.9% 54.5% External recruitement rate 35.4% ✔ PwC CH 37.1% 45.5% Employee total turnover rate (fluctuation) 8.5% ✔ PwC CH 10.0% 9.7% Percentage of voluntary turnover
5.2% ✔ PwC CH 6.1% 5.1% Percentage of Employer related Terminations 31.3% ✔ PwC CH 29.1% 40.3% Percentage of Neutral Terminations 6.9% ✔ PwC CH 10.1% 7.0% Percentage of Employee related Terminations 61.8% ✔ PwC CH 60.8% 52.6% Average training hours per employee based on our Learning Management Systems 32.2 ✔ PwC CH 39 35 Training costs per headcount (CHF) 1,501 ✔ PwC CH 1,398 1,474 Overall training costs (mCHF) 151 ✔ PwC CH 134 140 Total employees remuneration (mCHF) 16,262 ✔ PwC CH 15,336 14,533 - Total employees remuneration as % of sales 26.5% ✔ PwC CH 27.0% 27.3% Percentage of eligible employees that purchased shares through Roche CONNECT 48.1% ✔ PwC CH 47.3% 46.6% Number of peer-to-peer recognitions amongst employees 271,925 ✔ PwC CH 258,177 231,649
GEOS (employee survey) participation rate (6)
86% ✔ PwC CH na 90% GEOS (employee survey) engagement rate (6)
68% ✔ PwC CH na 72% Roche Accident Rate 0.044 ✔ PwC CH 0.048 0.048 Roche Illness Rate 0.013 ✔ PwC CH 0.014 0.011 Number of work related fatalities 1 ✔ PwC CH 0 0 Work-related accidents per 200,000 working hours 0.376 ✔ PwC CH 0.390 0.39 Occupational accidents 334 ✔ PwC CH 346 348 Occupational illnesses 113 ✔ PwC CH 154 155 Lost workdays per year 4,397 ✔ PwC CH 4,773 4,828 Average number of SHE training hours per participating employee 2.16 ✔ PwC CH 2.470 3.0
Being a trustworthy partner
Ban katantaOpen and constructive dialogue with our stakeholders is crucial to creatingsustainable value and growth. It helps us to better understand how to serve patients, their carers nd physicians, and to focus our activities on creating value for both the company and society.
-
See KPIs
KPI 2019 2018 2017 Number of new partnerships (7)
- in Pharma
- in Diagnostics
128
78
50
130
107
23
159
118
41
Number of business critical suppliers and service providers 1000 1000 1000 Suppliers completed Supplier CoC online training (6) 21,900 19,400 15,100 Number of sustainability audit conducted with suppliers 84 126 156 Number of Suppliers audited through PSCI (9) 76 105 68 Number of Suppliers with critical issue or discontinued based on audit results 0 2 8 Procurement spend with preferred suppliers (%) in direct spend 88% 88% 85% Grants and donations to healthcare organisations (mCHF) 175 ✔ PwC CH 198 122 - Education of patients and general public 3% ✔ PwC CH 4% 7% - Education of healthcare professionals 58% ✔ PwC CH 39% 42% - Research 20% ✔ PwC CH 11% 23% - Support for Healthcare infrastructure
16% ✔ PwC CH 14% 24% - Support for Personalized Healthcare and patient screening
3% ✔ PwC CH 3% 3% Grants and donations to patient organisations (mCHF) 33 ✔ PwC CH 40 31 Ban katanta- Financial contributions to Patient Organisations
97% ✔ PwC CH 94% 95% Ban katanta- Non-financial contributions to Patient Organisations
2% ✔ PwC CH 3% 2% - Service contracts with Patient Organisations 1% ✔ PwC CH 1% 3% - Sponsorships to Healthcare and patient Organisations (mCHF) 97 ✔ PwC CH 58 n.a. Income taxes (mCHF) 3,515 3,929 4,864 - Income taxes as % of sales 5.70% 6.90% 9.20% Community support by area: - - - - Humanitarian and social projects 90% ✔ PwC CH 94% 95% - Science and education 6% ✔ PwC CH 1% 1% - Arts and culture 2% ✔ PwC CH 2% 3% - Community and environment projects 2% ✔ PwC CH 3% 1% Roche Group Help & Advice Line Requests 16 39 38 Roche Group SpeakUp Line cases 182 131 176 Alleged Business Ethics Incident 543 601 685 Number of employees terminated due to unethical behavior 128 94 131 Number of other business partners terminated due to unethical behavior 13 19 4 Number of grievances about human rights impacts filed, addressed and resolved through formal grievance mechanism 8 18 0 more
Protecting the environment
Roche has been committed to mitigating environmental impact and climate change for many years, proactively seeking new, more sustainable technologies and processes to achieve this goal.
-
See KPIs
KPI 2019 2018 2017 Eco-balance (million impact points/employee) (11) 5.16 ✔ PwC CH 5.6 5.79 Total energy consumption (TJ/year) - Scope 1, 2, 3 (Business flights only) 11,822 ✔ PwC CH 11,939 12,089 Greenhouse gas emissions (tonnes CO2 equivalents) - Scope 1, 2, 3 (Business flights only) 685,446 ✔ PwC CH 749,139 769,256 Water consumption (million cubic meters per year) 3.1 ✔ PwC CH 3.4 3 Organic matter discharged to water ways after treatment (t/year) 127 ✔ PwC CH 185 144 Heavy metals discharged to water ways after treatment (kg/year) 228 ✔ PwC CH 149 129 Chemical waste generated (landfilled and incinerated waste in tonnes) 17,422 ✔ PwC CH 13,563 17,245 General waste generated (landfilled and incinerated waste in tonnes) 10,500 ✔ PwC CH 11,183 12,478 CDP Rating n.a. A- A- Energy intensity (GJ/employee) 117 ✔ PwC CH 119 120 Share (%) of sustainable energy in total energy consumption 24.1% ✔ PwC CH 21.3% 18.5% CO2 intensity (t/employee) 7.08 ✔ PwC CH 7.44 7.62 Total amount of SHE fines (significant) 0 ✔ PwC CH 0 0 Total spending for SHE measures (mCHF) 610 ✔ PwC CH 618 642 - Total SHE costs as % of sales 0.99% ✔ PwC CH 1.09% 1.20% more
Delivering continued growth
We aim to continuously create value for our stakeholders and to achieve sustainable, high profitability. We do this in order to maintain our commitment to research, to ensure our growth and independence, to provide employment opportunities, to cover risks, and to pay an attractive return on invested capital.
-
See KPIs
KPI 2019 2018 2017 Sales (mCHF) 61,466 56,846 53,299 Research and development core investments (mCHF) (12) 11,696 11,047 10,392 - Research and development as % of sales 19.00% 19.40% 19.50% M&D costs (mCHF) (12) 10,513 9,905 9,512 - M&D as % of sales 17.10% 17.40% 17.80% Core operating profit (mCHF) (12) 22,479 20,505 19,012 - Core operating profit margin 36.60% 36.10% 35.70% Net financial income (mCHF) (12) -903 -595 -745 IFRS Net Income (mCHF) 14,108 10,865 8,825 Core Earnings Per Share (CHF) 20.16 18.14 15.34 Operating free cash flow 20,921 18,741 17,827 - Operating free cash flow as % of sales 34.00% 33.00% 33.40% Net debt (mCHF) 2,505 5,652 6,963 Dividend per share (CHF) (13) 9 8.7 8.3 Dividend payments (bnCHF) (13) 7.763 7.504 7.159 Payout ratio (dividend per share divided by core EPS) 45% 48% 54% Market capitalisation (CHF billions) 268 207 210 Dow Jones World and FTSE4Good sustainability indexes 2nd Leader Leader
The marked figures (✔ PwC CH) were reviewed by the PricewaterhouseCoopers auditing firm.
(1) The patient number estimates how many treatments for specific diseases have been delivered in one year. It is based on the medicines sold and adjusted by average daily dose, treatment duration and compliance. Changes from 2018 to 2019 numbers are due to divestments.
Ban katanta(2) Patients included in interventional trials. Interventional trials refer to all Roche sponsored/funded and supported (eg. IIS, collaborative group, partner) studies incl phase 1-3, phase 4, where patients have been enrolled.
(3) Based on the , July 1st 2014
Ban katanta(4) Medicines launched in the US
(5) Top positions at corporate and operating Group level
(6) GEOS is not done on a yearly basis. Last surveys were conducted in 2017 and 2014.
(7) Partnerships also include license agreements, research and technology collaborations as well as clinical trial collaborations
(8) Audit Target: This refers to approximately 1 000 business critical suppliers, where we see the highest risk exposure and a five-year audit cycle. For our Diagnostics Division this also includes quality audits.
(9) PSCI audit reports or filled-in PSCI questionnaires
(10) Preferred Suppliers include critical, strategic and leverage suppliers, plus suppliers that are in scope of Supplier Diversity programs. 2015 figures: direct spend only.
(11) The Roche eco-balance refers to the consumption of energy and resources and the pollution caused by business activities. It thus describes the total environmental impact of our operations
(12) Core results exclude non-core items such as global restructuring charges and amortisation and impairment of goodwill and intangible assets
Ban katanta(13) For the year 2019 as proposed by the Board of Directors